Floatz logo

Rapamycin

Juvenile Myelomonocytic Leukemia (JMML)

St. Jude Children's Research HospitalPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

28 Active assets in the Juvenile Myelomonocytic Leukemia (JMML) cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Masonic Cancer Center, University of Minnesota
Phase 4BBB
Thiotepa
St. Jude Children's Research Hospital
Phase 3BBB
Busulphan
Masonic Cancer Center, University of Minnesota
Phase 4BBB
Fludarabine
Children's Oncology Group
Phase 3BB
CYCLOSPORIN A
Case Comprehensive Cancer Center
Phase 3BB

View all 46 →

Same molecule, other indications

Rapamycin is also rated in:

tuberous sclerosisDormant
BBB
Indicative ·
73 / 100
View asset →
disease related to transplantationDormant
BBB
Indicative ·
72 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →